CN102726683A - 含雌马酚的大豆胚轴发酵物 - Google Patents
含雌马酚的大豆胚轴发酵物 Download PDFInfo
- Publication number
- CN102726683A CN102726683A CN2012102391566A CN201210239156A CN102726683A CN 102726683 A CN102726683 A CN 102726683A CN 2012102391566 A CN2012102391566 A CN 2012102391566A CN 201210239156 A CN201210239156 A CN 201210239156A CN 102726683 A CN102726683 A CN 102726683A
- Authority
- CN
- China
- Prior art keywords
- plumular axis
- fermentate
- soybean plumular
- equol
- soybean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 214
- 244000068988 Glycine max Species 0.000 title claims abstract description 214
- 235000019126 equol Nutrition 0.000 title claims abstract description 100
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 title claims abstract description 100
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 title claims abstract description 100
- 239000000463 material Substances 0.000 title abstract description 8
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims abstract description 48
- 235000007240 daidzein Nutrition 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 239000002537 cosmetic Substances 0.000 claims abstract description 20
- -1 daidzein compound Chemical class 0.000 claims abstract description 11
- 229930182470 glycoside Natural products 0.000 claims abstract description 5
- 150000002338 glycosides Chemical class 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 36
- 150000001949 daidzein Chemical class 0.000 claims description 13
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 claims description 7
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 claims description 7
- 150000002272 genistein Chemical class 0.000 claims description 7
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 claims description 5
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 5
- 235000006539 genistein Nutrition 0.000 claims description 5
- 229940045109 genistein Drugs 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims description 3
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 claims description 3
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- MTXMHWSVSZKYBT-UHFFFAOYSA-N malonyl daidzin Natural products OC1C(O)C(O)C(COC(=O)CC(O)=O)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 MTXMHWSVSZKYBT-UHFFFAOYSA-N 0.000 claims description 3
- MTXMHWSVSZKYBT-ASDZUOGYSA-N malonyldaidzin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 MTXMHWSVSZKYBT-ASDZUOGYSA-N 0.000 claims description 3
- FRAUJUKWSKMNJY-UHFFFAOYSA-N 5-hydroxy-3-(4-hydroxyphenyl)-7-(6-malonyl-beta-D-glucopyranosyloxy)-4H-1-benzopyran-4-one Natural products OC1C(O)C(O)C(COC(=O)CC(O)=O)OC1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 FRAUJUKWSKMNJY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- UQGVUYNHDKMLSE-UHFFFAOYSA-N dihydrogenistein Chemical compound C1=CC(O)=CC=C1C1C(=O)C2=C(O)C=C(O)C=C2OC1 UQGVUYNHDKMLSE-UHFFFAOYSA-N 0.000 claims description 2
- FRAUJUKWSKMNJY-RSEYPYQYSA-N malonylgenistin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 FRAUJUKWSKMNJY-RSEYPYQYSA-N 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 14
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 8
- JHYXBPPMXZIHKG-CYBMUJFWSA-N Dihydrodaidzein Natural products C1=CC(O)=CC=C1[C@@H]1C(=O)C2=CC=C(O)C=C2OC1 JHYXBPPMXZIHKG-CYBMUJFWSA-N 0.000 abstract 1
- JHYXBPPMXZIHKG-UHFFFAOYSA-N dihydrodaidzein Chemical compound C1=CC(O)=CC=C1C1C(=O)C2=CC=C(O)C=C2OC1 JHYXBPPMXZIHKG-UHFFFAOYSA-N 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 description 37
- 230000004151 fermentation Effects 0.000 description 37
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 35
- 235000008696 isoflavones Nutrition 0.000 description 35
- 150000002515 isoflavone derivatives Chemical class 0.000 description 32
- 239000002994 raw material Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 17
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 16
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 16
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 16
- 229960003104 ornithine Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 9
- 239000004475 Arginine Substances 0.000 description 8
- 208000001132 Osteoporosis Diseases 0.000 description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 241000194017 Streptococcus Species 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 101710089395 Oleosin Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 229930182478 glucoside Natural products 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 101000767750 Carya illinoinensis Vicilin Car i 2.0101 Proteins 0.000 description 4
- 101000767759 Corylus avellana Vicilin Cor a 11.0101 Proteins 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 101000622316 Juglans regia Vicilin Jug r 2.0101 Proteins 0.000 description 4
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 description 4
- 241000194036 Lactococcus Species 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- 101000767757 Pinus koraiensis Vicilin Pin k 2.0101 Proteins 0.000 description 4
- 101000767758 Pistacia vera Vicilin Pis v 3.0101 Proteins 0.000 description 4
- 101710162629 Trypsin inhibitor Proteins 0.000 description 4
- 229940122618 Trypsin inhibitor Drugs 0.000 description 4
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 230000001076 estrogenic effect Effects 0.000 description 4
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 4
- 235000008466 glycitein Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 239000002753 trypsin inhibitor Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000194040 Lactococcus garvieae Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 241000219793 Trifolium Species 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241001135228 Bacteroides ovatus Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- HEZSALBPROZVOO-UHFFFAOYSA-N Dihydroglycitein Chemical compound C1OC=2C=C(O)C(OC)=CC=2C(=O)C1C1=CC=C(O)C=C1 HEZSALBPROZVOO-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001547082 Pseudobacillus Species 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 241000194008 Streptococcus anginosus Species 0.000 description 1
- 241001291896 Streptococcus constellatus Species 0.000 description 1
- 241000194046 Streptococcus intermedius Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HEZSALBPROZVOO-GFCCVEGCSA-N dihydroglycitein Natural products COc1cc2C(=O)[C@H](COc2cc1O)c3ccc(O)cc3 HEZSALBPROZVOO-GFCCVEGCSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- OZBAVEKZGSOMOJ-MIUGBVLSSA-N glycitin Chemical class COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZBAVEKZGSOMOJ-MIUGBVLSSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000013597 soy food Nutrition 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0636—Ornithine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2116—Flavonoids, isoflavones
- A23V2250/21172—Soy Isoflavones, daidzein, genistein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Abstract
本发明的目的在于提供含有雌马酚、作为食品原料、医药品原料或化妆品原料等有用的大豆胚轴发酵物。通过使用具有同化选自黄豆苷原糖苷、黄豆苷原及二氢黄豆苷原中的至少一种黄豆苷原类产生雌马酚的能力的微生物,使大豆胚轴发酵,由此制备含雌马酚的大豆胚轴发酵物。
Description
本申请是申请日为2006年12月05日、申请号为200680045856.4(国际申请号为PCT/JP2006/324255)、发明名称为“含雌马酚的大豆胚轴发酵物及其制备方法”的申请的分案申请。
技术领域
本发明涉及含有雌马酚(equol)的大豆胚轴(soybean embryonicaxis)发酵物及其制备方法。
背景技术
大豆中所含的异黄酮(大豆异黄酮;黄豆苷原(daidzein)、染料木黄酮(genistein)、黄豆黄素(glycitein))与雌二醇结构类似,具有随着与雌激素受体(以下表示为ER)的结合而产生的抗雌激素作用及雌激素样作用。迄今为止,大豆异黄酮的流行病学研究或介入研究提示了利用抗雌激素作用得到的乳癌、前列腺癌等激素依赖性癌的预防效果或利用雌激素样作用得到的更年期障碍、绝经后的骨质疏松症、高血脂症的改善效果。
近年,指出了上述大豆异黄酮的生理作用的活性本体可能是黄豆苷原的代谢物雌马酚。即,报道了与大豆异黄酮相比,雌马酚与ER的结合能力(特别是与ERβ结合)强,进入乳房或前列腺组织等目标脏器的移行性非常高。另外还报道了在患者-对照研究中乳癌、前列腺癌患者中雌马酚产生者显著少,将大豆异黄酮对绝经后的骨密度、脂质代谢的改善效果分为雌马酚产生者和非产生者进行解析时,雌马酚产生者显著被改善。
雌马酚由黄豆苷原经肠内细菌的代谢而产生,但是雌马酚产生能力具有个体差异,报道了日本人中的雌马酚产生者的比例约为50%。也就是说,日本人中有约50%不能产生雌马酚(雌马酚非产生者),在这些人中,即使摄取大豆或大豆加工食品,也无法享受基于雌马酚作用的有用的生理效果。因此,认为为了使雌马酚非产生者呈现基于雌马酚作用的有用生理效果,使其摄取雌马酚本身是有效的。
目前,作为雌马酚的制备方法,已知有用同化黄豆苷原产生雌马酚的微生物(以下表示为雌马酚产生菌)对含有黄豆苷原的原料进行发酵处理的方法。在该制备方法中,作为所用的含有黄豆苷原的原料,已知有大豆、葛根汤、红地球葡萄(red globe grape)、苜蓿等。另外,雌马酚产生菌也已经是公知的,例如,本发明人等从人类粪便中分离出了类杆菌E-23-15(FERM BP-6435号)、链球菌E-23-17(FERM BP-6436号)、链球菌A6G225(FERM BP-6437号)及乳球菌20-92(FERM BP-10036号)(参见专利文献1及2)。
但是,还存在下述问题:简单地使用雌马酚产生菌对含有上述黄豆苷原类的原料进行发酵处理,所得发酵物中的雌马酚量不充分,即使直接摄取该发酵物,也不能充分期待基于雌马酚作用的所希望的有用效果。
另一方面,已知与被用作大豆加工食品的子叶部分相比,大豆胚轴部分以高比例含有异黄酮或皂甙等有用成分,并对其提取物开发了各种用途(例如专利文献3)。但是,大豆胚轴提取物其本身具有成本高的缺点。另外,存在在大豆胚轴提出物用作制备雌马酚的原料时,为了用雌马酚产生菌进行发酵而必须另外添加营养素的问题。上述理由导致大豆胚轴提出物目前在工业上制备雌马酚时无法用作原料。
另一方面,因为大豆胚轴本身具有特有的苦味,所以具有避免直接利用该大豆胚轴本身的倾向,大部分大豆胚轴被丢弃。另外,大豆胚轴与大豆的子叶部分一样,含有过敏原物质,所以对具有大豆过敏的人来说,无法摄取或给予大豆胚轴。因此,为了有效利用大豆胚轴,通过使大豆胚轴本身进一步具有附加价值来提高其有用性是重要的。
专利文献1:国际公开第99/007392号说明书
专利文献2:国际公开第2005/000042号说明书
专利文献3:特开2002-234844号公报
发明内容
本发明的目的在于提供含有雌马酚的作为食品原料、医药品原料或化妆品原料等有用的大豆胚轴发酵物。进而,本发明的目的在于提供制备含雌马酚的大豆胚轴发酵物的方法。
本发明人等为了解决上述课题进行了深入的研究,结果发现使用具有同化黄豆苷原类产生雌马酚的能力的微生物使大豆胚轴发酵,能以高效率生成雌马酚,得到含雌马酚的大豆胚轴发酵物。进而发现,由于在由此所得的含雌马酚的大豆胚轴发酵物中降低了大豆胚轴所含的过敏原,所以作为低过敏原的原料也是有用的。基于上述认识,反复进行了改良,从而完成了本发明。
即,本发明提供涉及下述含雌马酚的大豆胚轴发酵物及其用途的发明:
项1.一种含雌马酚的大豆胚轴发酵物,是用具有同化选自黄豆苷原糖苷(daidzein glycosides)、黄豆苷原、及二氢黄豆苷原中的至少一种黄豆苷原类产生雌马酚的能力的微生物使大豆胚轴发酵而得到的。
项2.如项1所述的大豆胚轴发酵物,其中,所述微生物是属于乳球菌属的乳酸菌。
项3.如项1所述的大豆胚轴发酵物,其中,所述微生物是格氏乳球菌(Lactococcus garvieae)。
项4.如项1所述的大豆胚轴发酵物,其中,每干燥重量的大豆胚轴发酵物含有0.1~20重量%雌马酚。
项5.如项1所述的大豆胚轴发酵物,其中,所述大豆胚轴发酵物还含有黄豆苷(daidzin)类、染料木苷(genistin)类、染料木黄酮类、黄豆黄苷(glycitin)类及黄豆黄素类。
项6.如项1所述的大豆胚轴发酵物,其中,还含有鸟氨酸。
项7.一种食品,含有项1所述的大豆胚轴发酵物。
项8.如项7所述的食品,是膳食补充剂(dietary supplement)。
项9.如项7所述的食品,其中,每100g食品含有0.1~90g所述大豆胚轴发酵物。
项10.一种医药制剂,含有项1所述的大豆胚轴发酵物。
项11.如项10所述的医药制剂,是更年期障碍、骨质疏松症、前列腺肥大或代谢综合症的预防或治疗剂。
项12.如项10所述的医药制剂,是血中胆甾醇值的降低剂。
项13.项1所述的大豆胚轴发酵物在制备更年期障碍、骨质疏松症、前列腺肥大或代谢综合症的预防或治疗剂中的用途。
项14.项1所述的大豆胚轴发酵物在制备血中胆甾醇值的降低剂中的用途。
项15.一种更年期障碍的治疗方法,其特征在于,对更年期障碍的患者给予有效量的项1所述的大豆胚轴发酵物。
项16.一种血中胆甾醇值的降低方法,其特征在于,对需要降低血中胆甾醇值的患者给予有效量的项1所述的大豆胚轴发酵物。
项17.一种化妆品,含有项1所述的大豆胚轴发酵物。
项18.如项17所述的化妆品,其中,每100g化妆品含有0.1~10g所述大豆胚轴发酵物。
项19.一种含雌马酚的大豆胚轴发酵物的制备方法,其特征在于,用具有同化选自黄豆苷原糖苷、黄豆苷原及二氢黄豆苷原中的至少一种黄豆苷原类产生雌马酚的能力的微生物发酵处理大豆胚轴。
本发明的大豆胚轴发酵物由于含有雌马酚和除雌马酚以外的异黄酮或皂甙等有用成分,所以在食品、医药品、化妆品等领域中是有用的。特别是本发明的大豆胚轴发酵物与使大豆、葛根汤、红地球葡萄、苜蓿等含黄豆苷原的原料发酵所得的发酵物相比,雌马酚的生成量特别多,能进一步良好地发挥基于雌马酚的有用的生理效果。
进而,因为本发明的大豆胚轴发酵物降低了大豆胚轴中所含的过敏原,所以作为低过敏性原料,具有即使是对大豆过敏的人也能安全摄取或适用的优点。另外,本发明的大豆胚轴发酵物以大豆食品加工时被丢弃的大豆胚轴为原料,从有效利用资源的观点来看,产业上的利用价值高。
附图说明
[图1]是表示实施例1-3中所得的发酵液中的雌马酚浓度的图。
[图2]是表示检测实施例1中所得的大豆胚轴发酵物、大豆子叶及大豆胚轴中所含的总蛋白质的结果(电泳图)的图。
[图3]是表示检测实施例1中所得的大豆胚轴发酵物、大豆子叶及大豆胚轴所含的主要过敏原(Gym4、Gm30K、Gm28K)的结果(电泳图)的图。
[图4]表示实施例1中所得的大豆胚轴发酵物、大豆子叶及大豆胚轴中所含的主要过敏原(7S球蛋白mix、油质蛋白(oleosin)、胰蛋白酶抑制剂)的结果(电泳图)的图。
具体实施方式
以下,详细说明将本发明具体化的实施方式。
本发明中,作为雌马酚产生菌,使用具有同化选自黄豆苷原糖苷、黄豆苷原及二氢黄豆苷原中的至少一种黄豆苷原类产生雌马酚的能力(代谢活性)的微生物。此处,作为黄豆苷原糖苷,具体地可以举出黄豆苷、丙二酰黄豆苷、乙酰黄豆苷等。
作为上述微生物(雌马酚产生菌),只要食品卫生上允许并具有上述能力即可,没有特别限定,例如已知在下述微生物中存在具有上述能力的微生物:格氏乳球菌(Lactococcus garvieae)等属于乳球菌属的微生物;中间链球菌(Streptococcus intermedius)、咽峡炎链球菌(Streptococcus constellatus)等属于链球菌属的微生物;卵形假杆菌(Bacteroides ovatus)等属于类杆菌属的微生物。在雌马酚产生菌中,优选为乳球菌属及链球菌属等的乳酸菌,更优选属于乳球菌属的乳酸菌,特别优选举出格氏乳球菌。具有上述能力的微生物例如可以以有无雌马酚产生能力为指标,从人粪便中分离。对于上述雌马酚产生菌,已经保藏了由本发明人等从人类粪便分离鉴定的菌,即乳球菌20-92(FERM BP-10036号)、链球菌E-23-17(FERM BP-6436号)、链球菌A6G225(FERM BP-6437号)及类杆菌E-23-15(FERMBP-6435号),本发明中可以使用上述保藏菌。上述保藏菌中优选使用乳球菌20-92。
本发明中,发酵原料使用大豆胚轴。已知大豆胚轴是大豆发芽时形成幼芽、幼根的部分,含有大量黄豆苷原糖苷或黄豆苷原等黄豆苷原类。用于本发明的大豆胚轴限于所含黄豆苷原类没有流失的大豆胚轴,对大豆的产地或有无加工没有限定。例如可以是未加工的大豆胚轴;从经过加热处理、干燥处理、蒸煮处理等的大豆中分离出来的大豆胚轴;对从未加工的大豆分离得到的胚轴进行加热处理、干燥处理或蒸煮处理等得到的大豆胚轴等。另外,用于本发明的大豆胚轴可以是经过脱脂处理或脱蛋白质处理的大豆胚轴。对用于本发明的大豆胚轴的形状没有特别限定,可以为粉末状,也可以为被粉碎或破碎的大豆胚轴。从更有效地生成雌马酚的观点来看,优选使用粉末状大豆胚轴。
大豆胚轴的发酵处理通过在大豆胚轴中加入适量水调节水分含量,将上述雌马酚产生菌接种于其中而进行。
添加至大豆胚轴中的水的量根据所用的雌马酚产生菌的种类或发酵槽的种类等而适当设定。通常,在开始发酵时,大豆胚轴和水按以下的比例共存即可:相对于100重量份大豆胚轴(换算成干燥重量),水为400~4000重量份,优选为500~2000重量份,更优选为600~1000重量份。
另外,大豆胚轴的发酵中,为了促进发酵效率或增加发酵物的味道等,可以根据需要在作为发酵原料的大豆胚轴中添加酵母提取物、聚胨、肉羹等氮源;葡萄糖、蔗糖等碳源;磷酸盐、碳酸盐、硫酸盐等无机盐;维生素类;氨基酸等营养成分。特别是,作为雌马酚产生菌使用具有将精氨酸转化为鸟氨酸的能力的雌马酚产生菌(以下表示为“鸟氨酸·雌马酚产生菌”)时,在大豆胚轴中添加精氨酸进行发酵,由此可以使所得的发酵物中含有鸟氨酸。此时,精氨酸的添加量可以举出例如相对于100重量份大豆胚轴(换算成干燥重量),精氨酸为0.5~3重量份左右。需要说明的是,作为具有将精氨酸转化为鸟氨酸的能力的雌马酚产生菌,具体地可以选自格式乳球菌,具体而言,可以举出乳球菌20-92(FERM BP-10036号)。
进而,所用的发酵原料(大豆胚轴含有物)的pH只要能培育雌马酚产生菌即可,没有特别限定,从使雌马酚产生菌良好增殖的观点来看,优选预先将发酵原料的pH调节为6~7左右,优选为6.3~6.8左右。
另外,使用的发酵原料(大豆胚轴含有物)中还可以添加含有上述黄豆苷原类的异黄酮。由此通过预先另外在发酵原料中添加异黄酮,可以进一步提高所得的大豆胚轴发酵物中的雌马酚含量,从而进一步提高其有用性。
大豆胚轴的发酵在满足使用的雌马酚产生菌的培育特性的环境条件下进行。例如,使用上述具体列举的雌马酚产生菌时,大豆胚轴的发酵在厌氧性条件下进行。
另外,作为发酵温度,只要是适合雌马酚产生菌的生育的条件即可,例如可以举出20~40℃,优选举出35~40℃,更优选举出36~38℃。
发酵时间可以根据雌马酚的生成量、黄豆苷原类的残留量、雌马酚产生菌的种类等适当设定,通常可以为1~10日,优选为2~7日,更优选为3~5日。
在上述条件下进行发酵处理所得的大豆胚轴发酵物中生成并蓄积有雌马酚,可以呈现雌马酚的有用的生理作用。大豆胚轴发酵物中的雌马酚含量根据所使用的雌马酚产生菌或发酵条件等而不同,但通常每干燥重量的大豆胚轴发酵物(大豆胚轴发酵物的干燥重量为1g时),含有1~20mg、优选含有2~12mg、更优选含有5~8mg雌马酚。
大豆胚轴发酵物中除雌马酚以外,还可以含有黄豆苷、丙二酰黄豆苷、乙酰黄豆苷、黄豆苷原、二氢黄豆苷原等黄豆苷原类(以下,将这些成分表示为“黄豆苷原类”);染料木苷、丙二酰染料木苷、乙酰染料木苷、染料木黄酮、二氢染料木黄酮等染料木黄酮类(以下,将这些成分表示为“染料木黄酮类”);黄豆黄苷、丙二酰黄豆黄苷、乙酰黄豆黄苷、黄豆黄素、二氢黄豆黄素等黄豆黄素类(以下,将这些成分表示为“黄豆黄素类”)等各种异黄酮,也能呈现上述异黄酮的有用的生理活性。大豆胚轴发酵物中的异黄酮(含有雌马酚)的含量可以举出每1g干燥重量的大豆胚轴发酵物中,异黄酮为5~20mg,优选为5~15mg,更优选为8~15mg左右。
另外,从雌马酚以外的异黄酮的组成方面来看,大豆胚轴发酵物中的异黄酮具有与大豆胚轴所含的异黄酮不同的组成。特别是大豆胚轴发酵物中,有可能作为内分泌扰乱物质发挥作用的染料木黄酮类的总和相对于大豆胚轴发酵物的异黄酮总量的含有比例优选降低至15重量%以下,更优选降低至12重量%以下,从异黄酮的组成的观点来看,与发酵前的大豆胚轴相比,大豆胚轴发酵物是有利的。
作为大豆胚轴发酵物,具体地可以举出以下异黄酮组成的发酵物(以下的单位“mg”表示每1g(干燥重量)大豆胚轴发酵物中各异黄酮的总量):
雌马酚:1~20mg、优选2~12mg,
黄豆苷原类:0.1~30mg、优选0.1~1.5mg,
染料木黄酮类:0.05~2.5mg、优选0.05~2mg,
黄豆黄素类:0.1~4mg、优选2~3.5mg。
另外,大豆胚轴发酵物中所含的各异黄酮的组成比率可以举出以下所示的范围(以下的单位“重量%”表示相对于大豆胚轴发酵物中所含的全部异黄酮的总量的比例):
雌马酚:30~75重量%、优选40~70重量%、更优选45~70重量%,
黄豆苷原类:1~20重量%、优选2~15重量%、更优选4~12重量%,
染料木黄酮类:0.1~20重量%、优选1~15重量%、更优选1~10重量%,
黄豆黄素类:10~50重量%、优选15~35重量%、更优选25~35重量%。
由于本发明的大豆胚轴发酵物含有利用现有技术不能实现的组成的异黄酮,所以从其他观点来看,也可以说是具有上述异黄酮组成的异黄酮含有物质。
为了制备具有上述组成的异黄酮的大豆胚轴发酵物,特别优选使用乳球菌20-92(FERM BP-10036号)作为雌马酚产生菌。
进而,由于大豆胚轴发酵物中也含有来自大豆胚轴的皂甙,所以也可以获得基于皂甙作用的有用的生理活性(例如抗病毒活性等)。大豆胚轴发酵物中的皂甙含量如下:每1g干燥重量的大豆胚轴发酵物,含有10~80mg皂甙,优选为20~50mg,更优选为30~40mg。
如上所述,使用鸟氨酸·雌马酚产生菌并且将精氨酸添加至大豆胚轴中使其发酵所得的大豆胚轴发酵物中含有鸟氨酸。作为该大豆胚轴发酵物中所含的鸟氨酸的含量,具体地可以举出每1g干燥重量的大豆胚轴发酵物含有5~2mg、优选8~15mg、更优选9~12mg左右的鸟氨酸。
在上述条件下发酵处理得到的大豆胚轴发酵物可以以发酵后的状态直接用作食品、医药品、化妆品等的原料,另外,也可以根据需要进行干燥处理形成干燥固态物状,作为上述原料进行使用。为了提高大豆胚轴发酵物的保存稳定性,优选预先通过加热干燥处理形成固态状。另外,加热干燥处理后的大豆胚轴发酵物可以根据需要实施粉末化处理,制成粉末状。
如上所述,本发明的大豆胚轴发酵物含有雌马酚等各种有用的生理活性物质,所以能呈现各种生理活性或药理活性。例如,本发明的大豆胚轴发酵物对预防或改善更年期障碍、骨质疏松症、前列腺肥大、代谢综合症等疾病或症状、降低血中胆甾醇值、美白、改善粉刺、整肠、改善肥胖、利尿等是有用的。其中,本发明的大豆胚轴发酵物对预防或改善中老年女性的症状不定的自诉症状或伴随绝经出现的症状(例如骨质疏松症、更年期障碍等)特别有用。另外,使用鸟氨酸·雌马酚产生菌使含有精氨酸的发酵原料发酵所得的大豆胚轴发酵物中也生成·蓄积鸟氨酸,所以该大豆胚轴发酵物也可以得到改善肝功能、促进生长激素分泌、免疫赋活、增加肌肉量、改善基础代谢能力等基于鸟氨酸的有用的生理作用。
使用本发明的大豆胚轴发酵物作为食品原料时,该大豆胚轴发酵物例如可以调制成饮料、颗粒、细粒、胶囊、片剂、粉末、乳制品、口香糖、果胶糖(gum drop)、布丁、棒状食品(bar)、其他固态食品等形态。含有上述大豆胚轴发酵物的食品除雌马酚的有用的生理活性之外,也具有其他异黄酮或皂甙等的生理活性,所以有用性高,健保效果优异。另外,使用利用鸟氨酸·雌马酚产生菌使含有精氨酸的发酵原料发酵所得的大豆胚轴发酵物时,食品中也可以含有鸟氨酸,所以能进一步提高作为食品的有用性。
含有本发明的大豆胚轴发酵物的食品除可以用作一般的食品之外,也可以用作特定的保健用食品、膳食补充剂、功能性食品、患者用食品等。特别是含有本发明的大豆胚轴发酵物的食品作为膳食补充剂是有用的。
含有本发明的大豆胚轴发酵物的食品中,该食品中的该大豆胚轴发酵物的配合比例可以根据该食品的种类、雌马酚的含量、摄取对象的年龄或性别、被期待的效果等适当设定。可以举出下述一例,相对于100g上述食品,大豆胚轴发酵物(换算成干燥重量)的总量为0.1~90g、优选0.1~10g、更优选0.5~2g。
含有大豆胚轴发酵物的食品的一日摄取量根据大豆胚轴发酵物中的雌马酚含量、摄取者的年龄或体重、摄取次数等而不同,例如,成人1日的摄取量,可以举出相当于0.1~10g大豆胚轴发酵物的量。
另外,使用本发明的大豆胚轴发酵物作为医药品原料时,该大豆胚轴发酵物可以调制成片剂、丸剂、散剂、液体制剂、悬浊剂、乳剂、颗粒剂、胶囊剂、栓剂等形态的医药制剂。含有本发明的大豆胚轴发酵物的医药制剂作为更年期障碍(更年期的症状不定的自诉症状、骨质疏松症、高血脂症)、骨质疏松症、前列腺肥大、代谢综合症等疾病或症状的预防或改善剂、血中胆甾醇值的降低剂、整肠剂、肥胖改善剂、利尿剂等是有用的。特别是含有大豆胚轴发酵物的医药制剂优选用于预防或治疗中老年女性的症状不定的自诉症状或伴随绝经出现的症状(例如骨质疏松症、更年期障碍等)。
含有大豆胚轴发酵物的医药制剂的给与量根据大豆胚轴发酵物中的雌马酚含量、给药对象的年龄或体重、症状、给药次数等而不同,不能一律规定,例如,作为成人1日的给药量,可以举出大豆胚轴发酵物换算成干燥重量相当于0.5~6g的量。
进而,使用本发明的大豆胚轴发酵物作为化妆品的原料时,该大豆胚轴发酵物可以调制成糊状、摩丝状、凝胶状、液状、乳液状、悬浊液状、膏状、软膏状、薄片状等各种所希望的形态的化妆品。上述化妆品作为乳液、膏、洗液、油及膜等基础化妆品;洁面剂、洗涤剂、身体洗涤剂等洗涤剂;清洁擦拭剂;清洁剂等各种化妆品是有用的。含有本发明的大豆胚轴发酵物的化妆品可用作美白用化妆品、或粉刺改善用化妆品。
在含有本发明的大豆胚轴发酵物的化妆品中,该化妆品中的该大豆胚轴发酵物的配合比例可以根据该化妆品的种类、雌马酚的含量等适当设定。可以举出下述一例,相对于100g上述化妆品,大豆胚轴发酵物(换算成干燥重量)的总量为0.1~10g、优选为0.5~5。
实施例
以下,基于试验例、实施例等详细说明本发明,但本发明并不限定于这些实施例。
实施例1-3
按照表1所示的组成混合粉末状大豆胚轴、精氨酸及水,调制大豆胚轴溶液(原料)。在5ml该大豆胚轴溶液中接种乳球菌20-92株(FERM BP-10036号),在厌氧条件、37℃下静置培养96小时。培养后,将所得的发酵液(培养液)在100℃下加热杀菌1分钟,然后,在80℃的条件下干燥处理,进一步用均化器进行粉末化处理,得到粉末状的大豆胚轴发酵物。
图1表示培养96小时后培养液中的雌马酚浓度。同时,表1表示培养96小时后培养液中的活菌数及pH、粉末状的大豆胚轴发酵物的获取量、及粉末状的大豆胚轴发酵物中的雌马酚浓度。由该结果可确认,通过使用雌马酚产生菌使粉末状大豆胚轴发酵,可以以高效率生成雌马酚。
[表1]
#各实施例使用3个批次的粉末状大豆胚轴实施(N=3)。表中所示的分析结果为平均±SD值。
实施例4
在5ml含有10重量%粉末状大豆胚轴及0.1重量%L-精氨酸的大豆胚轴溶液中接种乳球菌20-92株(FERM BP-10036号),在厌氧条件、37℃下静置培养96小时,由此进行发酵处理。培养后,将所得的发酵液(培养液)在100℃的条件下加热杀菌1分钟,然后,在80℃的条件下进行干燥处理,进一步用均化器进行粉末化处理,由此得到粉末状的大豆胚轴发酵物。
分析作为原料使用的粉末状大豆胚轴(表2及3中表示为发酵前)及所得的粉末状大豆胚轴发酵物(表2及3中表示为发酵后)的含有成分。大豆异黄酮类的分析结果示于表2,营养成分的分析结果示于表3。由该结果也可确认,通过用乳球菌20-92株使大豆胚轴发酵,可以制备含有高含量的雌马酚的大豆胚轴发酵物。另外可以明确,蜜三糖或水苏糖等寡糖的含量在发酵前后为相同程度,几乎未受发酵的影响。另一方面,确认精氨酸通过发酵处理转化为鸟氨酸。因此,在大豆胚轴中添加精氨酸,用乳球菌20-92株进行发酵处理,由此不仅能生成雌马酚,还能生成鸟氨酸。
[表2]
N.D.表示未检出
[表3]
N.D.表示未检出
实施例5-11
除使用与上述实施例3不同的7个批次的粉末状大豆胚轴以外,在与上述实施例3相同的条件下制备粉末状大豆胚轴发酵物(实施例5-11)。分析所得的大豆胚轴发酵物中所含的异黄酮的组成。结果示于表4。由该结果可确认实施例5-11的大豆胚轴发酵物的雌马酚含量高,含有现有技术不能实现的组成的异黄酮。
[表4]
表中,上部的数值表示每1g大豆胚轴发酵物中的各异黄酮的含量(mg),下部的数值表示各异黄酮相对于大豆胚轴发酵物所含的异黄酮总量(100重量%)的比率(重量%)。
实施例12
除使用与上述实施例3不同批次的粉末状大豆胚轴以外,在与上述实施例3相同的条件下制备粉末状的大豆胚轴发酵物。每1g所得的大豆胚轴发酵物含有6.5mg雌马酚、0.6mg黄豆苷原类、0.6mg染料木黄酮类、3.2mg黄豆黄素类。另外,在该大豆胚轴发酵物中,苷原(aglycon)占异黄酮含量总量的90重量%以上。
使用由此得到的大豆胚轴发酵物,制成下述组成的片剂(每片的重量为2.51g,1片含有10.9mg雌马酚)。
实施例13
使用上述实施例12中使用的大豆胚轴发酵物,制备下述组成的颗粒。
实施例14
使用上述实施例1的大豆胚轴发酵物,调制以下组成的化妆品。
实施例15
使用上述实施例1的大豆胚轴发酵物,调制以下组成的化妆品。
试验例1
已知大豆胚轴中含有Gym4、Gm30K、Gm28K、7S球蛋白mix(β-大豆球蛋白(conglycine))、油质蛋白、胰蛋白酶抑制剂等过敏原。于是,用以下的试验判定上述实施例中制备的大豆胚轴发酵物中是否存在过敏原。
首先,将适量的实施例1中得到的大豆胚轴发酵物添加至提取缓冲液(Tris HCl pH7.5,含有1M EDTA、适量蛋白质分解酶抑制剂),充分搅拌,萃取水溶性成分。然后,通过过滤除去固态成分,得到提取液。用伯乐(bio-rad)公司制的蛋白质分析系统检测由此得到的提取液中所含的总蛋白质。进一步用蛋白免疫印迹(Western blotting)法检测所得的提取液中所含的主要过敏原(Gym4、Gm30K、Gm28K、7S球蛋白mix、油质蛋白、胰蛋白酶抑制剂)。另外,作为比较,使用大豆子叶粉末、及大豆胚轴粉末代替大豆胚轴发酵物,用相同的方法检测总蛋白质及过敏原。
结果示于图2~4。图2表示总蛋白质的检测结果;图3表示Gym4、Gm30K、及Gm28K的检测结果;图4表示7S球蛋白mix、油质蛋白、及胰蛋白酶抑制剂的检测结果。
由该结果可确认,大豆胚轴发酵物中降低了大豆或大豆胚轴中所含的主要过敏原。
Claims (6)
1.一种大豆胚轴发酵物,其中,相对于每1g干燥重量的大豆胚轴发酵物,含有1~20mg雌马酚及0.1~1.5mg选自黄豆苷、丙二酰黄豆苷、乙酰黄豆苷、黄豆苷原、及二氢黄豆苷原中的至少一种黄豆苷原类。
2.如权利要求1所述的大豆胚轴发酵物,其中,相对于每1g干燥重量的大豆胚轴发酵物,还含有0.05~2.5mg选自染料木苷、丙二酰染料木苷、乙酰染料木苷、染料木黄酮及二氢染料木黄酮中的至少一种染料木黄酮类。
3.如权利要求1或2所述的大豆胚轴发酵物,其中,所述大豆胚轴发酵物通过肠内细菌进行发酵。
4.如权利要求3所述的大豆胚轴发酵物,其中,肠内细菌为乳酸菌。
5.如权利要求1~4中任一项所述的大豆胚轴发酵物,其中,大豆胚轴中的过敏原的含量降低。
6.一种食品、医药品或化妆品,含有权利要求1所述的大豆胚轴发酵物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-352337 | 2005-12-06 | ||
JP2005352337 | 2005-12-06 | ||
JP2006277934 | 2006-10-11 | ||
JP2006-277934 | 2006-10-11 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800458564A Division CN101325881A (zh) | 2005-12-06 | 2006-12-05 | 含雌马酚的大豆胚轴发酵物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102726683A true CN102726683A (zh) | 2012-10-17 |
CN102726683B CN102726683B (zh) | 2015-04-01 |
Family
ID=38122801
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012102391975A Pending CN102845685A (zh) | 2005-12-06 | 2006-12-05 | 含雌马酚的大豆发酵物 |
CN201310591449.5A Pending CN103947960A (zh) | 2005-12-06 | 2006-12-05 | 含雌马酚的大豆胚轴发酵物及其制备方法 |
CN201310591447.6A Pending CN103947959A (zh) | 2005-12-06 | 2006-12-05 | 含雌马酚的大豆发酵物 |
CN201210239156.6A Active CN102726683B (zh) | 2005-12-06 | 2006-12-05 | 含雌马酚的大豆胚轴发酵物 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012102391975A Pending CN102845685A (zh) | 2005-12-06 | 2006-12-05 | 含雌马酚的大豆发酵物 |
CN201310591449.5A Pending CN103947960A (zh) | 2005-12-06 | 2006-12-05 | 含雌马酚的大豆胚轴发酵物及其制备方法 |
CN201310591447.6A Pending CN103947959A (zh) | 2005-12-06 | 2006-12-05 | 含雌马酚的大豆发酵物 |
Country Status (16)
Country | Link |
---|---|
US (5) | US20090311353A1 (zh) |
EP (3) | EP2474237B1 (zh) |
JP (5) | JP5030790B2 (zh) |
KR (4) | KR101346504B1 (zh) |
CN (4) | CN102845685A (zh) |
AR (2) | AR057220A1 (zh) |
AU (1) | AU2006323754B2 (zh) |
BR (2) | BR122018067616B1 (zh) |
CA (1) | CA2631850C (zh) |
ES (2) | ES2858674T3 (zh) |
HK (1) | HK1175661A1 (zh) |
MY (1) | MY169554A (zh) |
PH (1) | PH12014500480A1 (zh) |
TR (1) | TR201807884T4 (zh) |
TW (2) | TWI491732B (zh) |
WO (1) | WO2007066655A1 (zh) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
EP1569636B1 (en) | 2002-10-29 | 2017-12-13 | Colorado State University Research Foundation | Use of equol for treating androgen mediated diseases |
MY169554A (en) * | 2005-12-06 | 2019-04-22 | Otsuka Pharma Co Ltd | Equal-containing fermentation product of soybean embryonic axis, and method for production thereof |
CN102919738B (zh) * | 2007-06-13 | 2016-05-11 | 大塚制药株式会社 | 含雌马酚的提取物、其制备方法、雌马酚的提取方法及含雌马酚的食品 |
PT2404995E (pt) * | 2007-12-27 | 2013-09-26 | Otsuka Pharma Co Ltd | Enzima associada à síntese de equol |
US20110117227A1 (en) * | 2008-07-31 | 2011-05-19 | Coreana Cosmetics, Co., Ltd. | Cosmetic composition for anti-aging of the skin comprising phaseolus radiatus seed extracts by fermentation and enzyme treatment |
AU2014240200B2 (en) * | 2008-09-19 | 2015-08-13 | Otsuka Pharmaceutical Co., Ltd. | Fermentation product containing equol-producing microorganism having maintained equol-producing ability, and method for producing same |
MY158628A (en) * | 2008-09-19 | 2016-10-31 | Otsuka Pharma Co Ltd | Fermentation product containing equol-producing microorganism having maintained equol-producing ability, and method for producing same |
JP5777287B2 (ja) * | 2009-09-18 | 2015-09-09 | 大塚製薬株式会社 | エクオール産生能が維持されたエクオール産生微生物を含む発酵製品、及びその製造方法 |
JP5780651B2 (ja) * | 2009-09-18 | 2015-09-16 | 不二製油株式会社 | エクオールの不斉合成法 |
JP5851685B2 (ja) * | 2010-12-24 | 2016-02-03 | 株式会社ダイセル | エクオールの製造方法、エクオール産生組成物、食品、食品添加物及び医薬品 |
JP5851686B2 (ja) * | 2010-12-24 | 2016-02-03 | 株式会社ダイセル | エクオールの製造法、エクオール産生組成物、食品、食品添加物及び医薬品 |
JP5851687B2 (ja) * | 2010-12-24 | 2016-02-03 | 株式会社ダイセル | エクオールの製造方法、エクオール産生組成物、食品、食品添加物及び医薬品 |
JP6005453B2 (ja) * | 2012-09-14 | 2016-10-12 | 株式会社ダイセル | オルニチンとエクオールを含む組成物 |
JP6371055B2 (ja) * | 2013-12-20 | 2018-08-08 | 株式会社ダイセル | イソフラバノン類の製造方法 |
JP2015139424A (ja) * | 2014-01-30 | 2015-08-03 | 株式会社ダイセル | エクオール含有組成物の製造方法 |
JP2015168668A (ja) * | 2014-03-10 | 2015-09-28 | 株式会社ダイセル | エクオールを含有する抗糖化剤 |
JP6512548B2 (ja) * | 2015-04-03 | 2019-05-15 | 株式会社ダイセル | エクオール、酸化防止剤、及び油類を含有する外用組成物 |
WO2017057455A1 (ja) * | 2015-09-29 | 2017-04-06 | 株式会社カネカ | 発酵食品組成物の製造方法 |
TWI774660B (zh) * | 2016-03-08 | 2022-08-21 | 日商大塚製藥股份有限公司 | 女性特有之身體及/或精神不快症狀之改善劑 |
JP7068816B2 (ja) * | 2017-12-15 | 2022-05-17 | 大塚製薬株式会社 | エクオールおよびコラーゲンペプチドを含有する経口組成物 |
KR102064055B1 (ko) * | 2018-02-08 | 2020-01-08 | 신선옥 | 에쿠올이 생성된 발효커피생두, 그 제조방법 및 그 추출물 |
JP6486529B1 (ja) * | 2018-03-19 | 2019-03-20 | 室戸海洋深層水株式会社 | 腸内フローラ改善健康食品 |
JP2022022349A (ja) * | 2018-10-24 | 2022-02-03 | 株式会社ダイセル | エクオール含有組成物の製造方法 |
JP2019011370A (ja) * | 2018-10-24 | 2019-01-24 | 株式会社ダイセル | エクオール含有組成物の製造方法 |
KR20200070502A (ko) | 2018-12-07 | 2020-06-18 | 전북대학교산학협력단 | 에쿠올함유 발효커피음료 및 그 제조방법 |
US20220257676A1 (en) | 2019-07-24 | 2022-08-18 | Asahi Group Holdings, Ltd. | Agent for regulating female hormone secretion and agent for alleviating unpleasant symptoms |
KR102124400B1 (ko) * | 2019-12-17 | 2020-06-18 | 주식회사 비앤비코리아 | 담자균류균사의 액상배양공정에 의한 천문동 및 대두배아의 생물전환산물을 포함하는 미세먼지 세정용 화장료 조성물 |
JP7479833B2 (ja) | 2019-12-18 | 2024-05-09 | 小林製薬株式会社 | エストロゲン様活性剤組成物 |
JP7479832B2 (ja) | 2019-12-18 | 2024-05-09 | 小林製薬株式会社 | 経口組成物 |
JPWO2021235278A1 (zh) * | 2020-05-21 | 2021-11-25 | ||
JP2022132404A (ja) * | 2021-12-07 | 2022-09-08 | 株式会社ダイセル | エクオール含有組成物の製造方法 |
JP2023105251A (ja) * | 2022-07-13 | 2023-07-28 | 株式会社ダイセル | エクオール含有組成物の製造方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1265596A (zh) * | 1997-08-08 | 2000-09-06 | 大塚制药株式会社 | 含异黄酮的组合物 |
WO2004009035A2 (en) * | 2002-07-24 | 2004-01-29 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
WO2005000042A1 (ja) * | 2003-06-30 | 2005-01-06 | Otsuka Pharmaceutical Co., Ltd. | エクオール産生乳酸菌含有組成物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0761241B2 (ja) | 1989-07-07 | 1995-07-05 | マルサンアイ株式会社 | 大豆胚軸の発酵生産物並にその製造法 |
EP0656786B2 (en) * | 1992-05-19 | 2014-04-23 | Novogen Research Pty Ltd | Use of isoflavone phyto-oestrogen extracts of soy or clover |
AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
ATE338812T1 (de) * | 1997-10-17 | 2006-09-15 | Nestle Sa | Neuer laktobakterienstamm |
ES2232107T3 (es) * | 1998-01-12 | 2005-05-16 | Nichimo Kabushiki Kaisha | Proceso para la preparacion de compuestos de isoflavona. |
JP3497083B2 (ja) | 1998-09-21 | 2004-02-16 | 不二製油株式会社 | 乳酸発酵豆乳の製造法 |
US20030044475A1 (en) * | 2000-03-24 | 2003-03-06 | Van De Wiel Andriaan Emanuel Hendricus Anna Maria | Cosmetic use of hop and ornithine |
JP2002234844A (ja) | 2000-12-05 | 2002-08-23 | Toyo Seito Kk | 骨密度向上剤およびその利用 |
CN1373206A (zh) * | 2001-02-28 | 2002-10-09 | 三照全盛特有限公司株式会社 | 使用大豆胚芽制得的曲及其制造方法以及用其制造的酱类 |
AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
JP4212838B2 (ja) | 2002-06-26 | 2009-01-21 | カルピス株式会社 | 抗アレルギー剤 |
JP2004033092A (ja) | 2002-07-02 | 2004-02-05 | Aomori Prefecture | 植物性エストロゲン誘導体のえぐ味改善方法、ならびにそれを利用した納豆または納豆食品、およびその製造方法 |
JP2003081855A (ja) | 2002-08-19 | 2003-03-19 | Yakult Honsha Co Ltd | 脂質代謝改善剤およびそれを含有する食品 |
JP2004236523A (ja) | 2003-02-04 | 2004-08-26 | Hidehachiro Kato | 醗酵食品及びその製造方法 |
JP4889979B2 (ja) * | 2005-08-30 | 2012-03-07 | 浜松ホトニクス株式会社 | X線源 |
MY169554A (en) * | 2005-12-06 | 2019-04-22 | Otsuka Pharma Co Ltd | Equal-containing fermentation product of soybean embryonic axis, and method for production thereof |
JP6005453B2 (ja) | 2012-09-14 | 2016-10-12 | 株式会社ダイセル | オルニチンとエクオールを含む組成物 |
-
2006
- 2006-12-05 MY MYPI20081910A patent/MY169554A/en unknown
- 2006-12-05 EP EP12160323.7A patent/EP2474237B1/en active Active
- 2006-12-05 CN CN2012102391975A patent/CN102845685A/zh active Pending
- 2006-12-05 WO PCT/JP2006/324255 patent/WO2007066655A1/ja active Application Filing
- 2006-12-05 US US12/095,828 patent/US20090311353A1/en not_active Abandoned
- 2006-12-05 BR BR122018067616-7A patent/BR122018067616B1/pt active IP Right Grant
- 2006-12-05 EP EP06834010A patent/EP1961309A4/en not_active Withdrawn
- 2006-12-05 ES ES18160164T patent/ES2858674T3/es active Active
- 2006-12-05 KR KR1020137005149A patent/KR101346504B1/ko active IP Right Grant
- 2006-12-05 CA CA2631850A patent/CA2631850C/en active Active
- 2006-12-05 CN CN201310591449.5A patent/CN103947960A/zh active Pending
- 2006-12-05 KR KR1020087016359A patent/KR101195706B1/ko active IP Right Grant
- 2006-12-05 CN CN201310591447.6A patent/CN103947959A/zh active Pending
- 2006-12-05 AR ARP060105357A patent/AR057220A1/es not_active Application Discontinuation
- 2006-12-05 KR KR1020117028321A patent/KR101306362B1/ko active IP Right Grant
- 2006-12-05 EP EP18160164.2A patent/EP3351258B1/en active Active
- 2006-12-05 KR KR1020137021167A patent/KR101329921B1/ko active IP Right Grant
- 2006-12-05 TR TR2018/07884T patent/TR201807884T4/tr unknown
- 2006-12-05 BR BRPI0619484A patent/BRPI0619484A8/pt not_active Application Discontinuation
- 2006-12-05 CN CN201210239156.6A patent/CN102726683B/zh active Active
- 2006-12-05 AU AU2006323754A patent/AU2006323754B2/en active Active
- 2006-12-05 JP JP2007549133A patent/JP5030790B2/ja active Active
- 2006-12-05 ES ES12160323.7T patent/ES2672871T3/es active Active
- 2006-12-06 TW TW095145394A patent/TWI491732B/zh active
- 2006-12-06 TW TW102115070A patent/TWI491733B/zh active
-
2009
- 2009-03-03 HK HK13102813.6A patent/HK1175661A1/zh unknown
-
2012
- 2012-03-30 JP JP2012082486A patent/JP5535263B2/ja active Active
- 2012-07-03 JP JP2012149675A patent/JP5697633B2/ja active Active
- 2012-07-16 US US13/549,568 patent/US20120277302A1/en not_active Abandoned
- 2012-07-16 US US13/549,686 patent/US9386786B2/en active Active
-
2013
- 2013-10-08 AR ARP130103634A patent/AR092932A2/es not_active Application Discontinuation
-
2014
- 2014-02-20 JP JP2014030933A patent/JP5734477B2/ja active Active
- 2014-03-03 PH PH12014500480A patent/PH12014500480A1/en unknown
- 2014-04-15 JP JP2014083507A patent/JP5946489B2/ja active Active
-
2018
- 2018-04-18 US US15/956,427 patent/US20180235260A1/en not_active Abandoned
-
2022
- 2022-09-29 US US17/955,898 patent/US20230270142A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1265596A (zh) * | 1997-08-08 | 2000-09-06 | 大塚制药株式会社 | 含异黄酮的组合物 |
WO2004009035A2 (en) * | 2002-07-24 | 2004-01-29 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
WO2005000042A1 (ja) * | 2003-06-30 | 2005-01-06 | Otsuka Pharmaceutical Co., Ltd. | エクオール産生乳酸菌含有組成物 |
Non-Patent Citations (2)
Title |
---|
夏延斌: "《食品化学》", 30 June 2001, 中国轻工业出版社 * |
李喜宏等: "《大豆及豆类保鲜与加工技术》", 31 January 2009, 中国农业出版社 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102726683B (zh) | 含雌马酚的大豆胚轴发酵物 | |
TW580517B (en) | Isoflavone-containing composition | |
Afzaal et al. | Nutritional health perspective of natto: A critical review | |
CN103652346A (zh) | 复合益生菌发酵豆粕饲料提高大豆异黄酮转化率的方法 | |
CN101325881A (zh) | 含雌马酚的大豆胚轴发酵物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1175661 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1175661 Country of ref document: HK |